T. Rowe Price - Home
Choose your site Enterprise Corporate Personal Investing Workplace Retirement Institutional Investors/Consultants Financial Intermediary Retirement Plan Sponsors / Consultants Oak Hill Advisors, L.P. (OHA) – External Site
Your location and language
English
Search
Choose your site Enterprise Corporate Personal Investing Workplace Retirement Institutional Investors/Consultants Financial Intermediary Retirement Plan Sponsors / Consultants Oak Hill Advisors, L.P. (OHA) – External Site
Your location and language
English
Your location and language
English
Home / Insights / Healthcare Innovation

Healthcare Innovation

October 2024 / EQUITY

Key considerations for global equities beyond the U.S. election

Key considerations for global equities beyond the U.S. election

Key considerations for global equities beyond...

Powerful factors provide a relatively positive backdrop for equity markets in 2025.

By David J. Eiswert

David J. Eiswert Portfolio Manager

August 2024 / EQUITY

Are GLP-1s the next industry disruptor?

Are GLP-1s the next industry disruptor?

Are GLP-1s the next industry disruptor?

Some are predicting that GLP-1s could pose a disruptive threat to the medtech industry.

By Taymour Tamaddon

Taymour Tamaddon Portfolio Manager

August 2024 / EQUITY

Why balance is important amid equity market volatility

Why balance is important amid equity market volatility

Why balance is important amid equity market...

Geopolitics, sticky inflation, and peaking earnings growth point to elevated volatility. ...

By David J. Eiswert & Nabil Hanano

By David J. Eiswert & Nabil Hanano

June 2024 / VIDEO

Two Questions on U.S. Equities with Julian Cook

Two Questions on U.S. Equities with Julian Cook

Two Questions on U.S. Equities with Julian...

Portfolio Specialist Julian Cook discusses his outlook and expectations for U.S....

By Julian Cook

Julian Cook Portfolio Specialist

September 2024 / ESG

Could GLP-1s help rebalance the food trilemma?

Could GLP-1s help rebalance the food trilemma?

Could GLP-1s help rebalance the food trilemma?

Anti-obesity medications could play a key role in balancing the food trilemma.

By Maria Elena Drew & Daniel Ryan

By Maria Elena Drew & Daniel Ryan

August 2024 / EQUITY

Artificial intelligence, health care, and energy transition: Three areas...

Artificial intelligence, health care, and energy transition: Three areas...

Artificial intelligence, health care, and...

How innovations in artificial intelligence, health care, and the energy transition...

By Hari Balkrishna

Hari Balkrishna Portfolio Manager

June 2024 / EQUITY

Assessing the potential impacts on U.S. health care in an election year

Assessing the potential impacts on U.S. health care in an election year

Assessing the potential impacts on U.S. health...

The potential impact and implications for U.S. health care could differ greatly depending...

By Jill Jortner

Jill Jortner Investment Analyst

202502-4090360

Download

Latest Date Range
Audience for the document: Share Class: Language of the document:
Download Cancel

Open

Share Class: Language of the document:
Open Cancel
Sign in to manage subscriptions for products, insights and email updates.
Continue with sign in?
To complete sign in and be redirected to your registered country, please select continue. Select cancel to remain on the current site.
Continue Cancel
Once registered, you'll be able to start subscribing.
Continue Back

Change Details

If you need to change your email address please contact us.
Change password
Save Cancel
Subscriptions
OK
You are ready to start subscribing.
Get started by going to our products or insights section to follow what you're interested in.

Products Insights

GIPS® Information

T. Rowe Price ("TRP") claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS standards. T. Rowe Price has been independently verified for the 27-year period ended June 30, 2023, by KPMG LLP. The verification report is available upon request. A firm that claims compliance with the GIPS standards must establish policies and procedures for complying with all the applicable requirements of the GIPS standards. Verification provides assurance on whether the firm’s policies and procedures related to composite and pooled fund maintenance, as well as the calculation, presentation, and distribution of performance, have been designed in compliance with the GIPS standards and have been implemented on a firm-wide basis. Verification does not provide assurance on the accuracy of any specific performance report.

TRP is a U.S. investment management firm with various investment advisers registered with the U.S. Securities and Exchange Commission, the U.K. Financial Conduct Authority, and other regulatory bodies in various countries and holds itself out as such to potential clients for GIPS purposes. TRP further defines itself under GIPS as a discretionary investment manager providing services primarily to institutional clients with regard to various mandates, which include U.S, international, and global strategies but excluding the services of the Private Asset Management group.

A complete list and description of all of the Firm's composites and/or a presentation that adheres to the GIPS® standards are available upon request. Additional information regarding the firm's policies and procedures for calculating and reporting performance results is available upon request. 

Other Literature

You have successfully subscribed.

Notify me by email when
regular data and commentary is available
exceptional commentary is available
new articles become available

Thank you for your continued interest